|
|
||||
![]() |
Saturday Jun 07
|
|||
| |
||||
4Q Profit Drops 44% for Mentor Corp.by MT Bureau - May 19, 2005 - 0 comments
Mentor Corp., a maker of health care products ranging from breast implants to disposable catheters, said Wednesday that profit dropped 44 percent in a fiscal fourth quarter weighed down by special charges. However, sales rose and adjusted results beat Wall Street estimates. The company’s shares were halted in after-hours trading, having closed earlier up 3.5 percent at $ 39.70 on the New York Stock Exchange. For the three months ended March 31, Mentor earned $ 8.4 million, or 19 cents per share, down from $ 15 million, or 31 cents per share, a year ago. Excluding items such as severance payments and asset devaluation as part of a large restructuring program, the company said it would have earned 42 cents per share. Revenue rose 12 percent to $ 131.6 million from $ 117.3 million. The company’s cosmetic surgery business posted 13 percent growth to sales of $ 68.7 million while revenue increased 18 percent for its urology segment to $ 35.1 million. The company’s clinical and consumer health care unit posted a more modest 5 percent sales increase to $ 27.8 million. Favorable exchange rates contributed about $ 2.6 million of overall growth, Mentor said. Analysts expected earnings of 37 cents per share, after adjustments, on sales of $ 128.9 million, according to a Thomson Financial survey. For the year, earnings inched up to $ 54.9 million, or $ 1.17 per share, from $ 54.8 million, or $ 1.13 per share. Revenue grew 15 percent to $ 483.4 million. Excluding items, the company’s year-end profit would have been $ 1.40 per share. Analysts were looking for adjusted profit of $ 1.34 per share and sales of 480.3 million. For 2006, Mentor predicted that sales growth will be in the low double digits, leading to earnings of $ 1.60 to $ 1.65 per share. Analysts expect profit of $ 1.56 per share with sales growing 11 percent to $ 535.9 million. The company said its 2006 forecast excludes any contribution from a silicone gel breast implant that is currently awaiting regulatory approval. |
|
||||||
Disclaimer: The views and investment tips expressed by investment experts on themoneytimes.com are their own, and not that of the website or its management. TheMoneyTimes advises users to check with certified experts before taking any investment decision. ©2004-2008 All Rights Reserved unless mentioned otherwise. [Submit News/Press Release][Terms of Service] [Privacy Policy] [About us] [Contact us] |